Navigation Links
Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
Date:5/30/2008

PRINCETON, N.J., May 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to host a webcast review of the ipilimumab data presented during the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. As previously announced, the live webcast will begin at 8:00 a.m. Eastern Time / 7:00 a.m. Central Time on Monday, June 2, 2008. Medarex senior management will be joined by Jedd D. Wolchok, M.D., Ph.D., Director of Immunotherapy Clinical Trials at Memorial Sloan-Kettering Cancer Center in New York.

The webcast can be accessed on Medarex's website at http://www.medarex.com and will be archived and available for at least 14 days.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medarex Announces 2008 First Quarter Financial Results
2. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
3. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
4. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
6. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
7. Medarex to Present at the JPMorgan Small/Mid Cap Conference
8. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
9. SNM hosts 55th Annual Meeting of Nuclear Medicine and Molecular Imaging Research
10. TriWest Hosts Military Heroes at National Memorial Day Parade
11. American Red Cross Hosts Heritage of Service Dinner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Pass, OR (PRWEB) , ... April 29, 2016 , ... ... suggest dinner as the meal to miss. That was among the many new lifestyle ... Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny and ...
(Date:4/29/2016)... ... , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. Mickey ... -- are proud of the recent release of their 2014 in vitro fertilization success ... published the latest verified data for 375 U.S. member clinics. *Preliminary data shows HRC/OC ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in ... efficacy of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The ... adding BC and AD, saying it is time to set the record straight. Traditionally, ... says this simply cannot possibly be true and offers explanation. , “To start with, ...
(Date:4/28/2016)... ... April 29, 2016 , ... Sublime Beauty® is offering a special deal on its webstore. ... off. The discount is applied to the product with lesser value. In addition, a ... purchase $250 or more in products. , "So many women (men, too) love our products ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
(Date:4/26/2016)... 2016 US demand for infection prevention ... percent annually to $27.6 billion in 2020.  Increasing ... decrease rates of healthcare-associated infections (HAIs) will boost ... services.  Although declining, the overall rate of certain ... set by the CDC.  Recent statistics indicate that ...
Breaking Medicine Technology: